AFYX
REVERSED INNOVATION

WHAT

We **find** new indications for existing technologies.

WHY

We improve lives by addressing unmet medical needs.

01

A HISTORY OF REVERSED INNOVATION



02

INVESTMENT OPPORTUNITY

03

INDICATIONS FOR EXISTING TECHNOLOGIES

04

PROTECTED FROM COMPETITION

A HISTORY OF REVERSED INNOVATION

MERGING DECADES OF TECHNOLOGY

AFYX is a Biopharmaceutical company with focus on reformulation and repurposing of pharmaceuticals.

2014: AFYX THERAPEUTICS
Development of a proprietary patented patch technology that sticks to wet surfaces

2015: LIONHEART PHARMACEUTICALS
Treatment of chronic and intermittent cluster headache.

2017: INPHENA PAIN & CANCER
Research, development and sales of repurposed existing pharmaceutical.

2024: MERGE: AFYX THERAPEUTICS
A history of Reversed Innovation. Biopharmaceutical company established through a merger of the above companies.



THE MEANING OF REVERSED INNOVATION

We find new indications for existing technologies.

Through our research, **we work relentlessly to improve lives by** addressing unmet medical needs.

As a leader in the biopharma area of **reversed innovation** we take an existing product or technology and use to it to address a new or previously overlooked or unconsidered medical problem or condition.

DR. CLAUS J. MØLLER-SAN PEDRO
CEO

TRUSTED DEVELOPMENT

Dr. Claus J. Møller-San Pedro is the company CEO.

Dr. Møller co-founded and participated in securing successful IPOs of 3 companies in the BioPharma Industry:

OXiGENE Inc. (OTLC)
Genmab A/S (GMAB)
Y-mAbs Therapeutics, Inc. (YMAB)

BOARD OF DIRECTORS 2025

DR OLE BAADSGAARD

BOD Member, Chairman

DR CLAUS MØLLER-SAN PEDRO

CEO, BOD Member

MS PIA MØLLER-SAN PEDRO

BOD Member & SVPI nt'l Marketing & Logistics

MR SØREN KJÆR

Working BOD Member

OUR
TECHNOLOGIES

PIPELINE


PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILING
LAUNCH
Head & Neck cancer
AFYX-001 – Nimorazole
Addiction
AFYX-002 – Diamorphine & Buprenorphine
Labor Induction
AFYX-003 - Misoprostol
EU
US
Cluster Headache
AFYX-004 – Esketamine Nasal
OLP
AFYX-005 - Patch w/clobetasol
VLS
AFYX-005 - Patch w/clobetasol
RAS
AFYX-005 - Patch w/clobetasol
OPML/H&N
AFYX-006/007 - Patch w/chemo

NIMORAZOLE

THE UNMET NEED:

Designed to increase the efficacy of radiation therapy by mimicking the effects of oxygen in the tumor and inducing **hypoxic tumor cells** to be more susceptible to radiation therapy.

- **NIMORAZOLE**
- ESKETAMINE
- RIVELIN
- MISOPROSTOL

HEAD & NECK CANCER

Blue Ocean market. No competition.

50,000 EU TREATMENTS

Receive front line radiation treatment for SCCHN every year.

DIAGNOSED

All patients are diagnosed and scheduled for radiation.

+$250M/YEAR POTENTIAL IN EUROPE

Expected EU price of around €10.000 for full treatment in EU.

ESKETAMINE

THE UNMET NEED:

An innovative approach to treat treatment of Cluster Headache.

- NIMARAZOLE
- **ESKETAMINE**
- RIVELIN
- MISOPROSTOL

SUICIDE HEADACHE
Improving daily living, quality of life and reduce the socioeconomic impact.

8 MILLION+ AFFECTED
60% of patients reported Complete or Moderate pain relief after 30 min.

NO ACCESS TO TREATMENTS
25% has no or low access to treatment.

$+500M / YEAR POTENTIAL in Europe alone.

RIVELIN

THE UNMET NEED:

- NIMARAZOLE
- ESKETAMINE
- **RIVELIN**
- MISOPROSTOL

RIVELIN PATCH TECHNOLOGY

THE UNMET NEED:

Multiple local diseases affect wet surfaces such as cavum oris (the mouth) and the vagina. Ordinary patches will not stick to such surfaces making precise and correct local application of pharmaceuticals very difficult. Our electrospun Rivelin Patch Technology is precisely addressing these problems and therefore has potential in a number of both immunological and malignant conditions.

MISOPROSTOL

THE UNMET NEED:

Misoprostol® is a 25-microgram misoprostol tablet developed and indicated for induction of labor.

- NIMARAZOLE
- ESKETAMINE
- RIVELIN
- **MISOPROSTOL**

OBSTERICS PRODUCT
Recommended by WHO in 2011 as first line option for induction of labor.

1,200,000 TREATMENTS in EU
One induction per patient per year.

ORAL ADMINSTRATION
Small oral tablet formulated with the recommended dose of misoprostol by WHO.

ANNUAL POTENTIAL
The global market potential is more than $300M.

SUMMARY

Powering Growth:

- ✓ Cash Flow
- ✓ Development
- ✓ Market Expansion

Proven cash flow generation:
Significant revenues from existing products with DKK 36M in 2024 and projected growth to DKK +200M by 2028

Two new drugs launching soon:
Misoprostol: EU registration expected Q1 2026, launch Q4 2026 Nimorazole: Regulatory filing Q3 2026, expected launch Q1 2028

Large market opportunities:
Our products address markets with a potential of several hundred millions – e.g., Nimorazole alone has potential to generate sales of DKK >1.0BN annually for Head & Neck Cancer treatment

Robust pipeline:
Multiple innovative products and expansion into new markets support continued growth

AFYX

THANK YOU!

afyxtx.com

+45 7174 7174

info@afyxtx.com